About Turkey medical device registration, quite a few ‘standard answers’ circulate online: an import licence is required, registration certificates renew every five years, Class I clears in a week, and official fees are a few hundred lira.
Most of these claims do not survive a check against the original texts.
Part 1: Regulatory Framework – First, Get Clear on Who Regulates and Under What
Q1 Who regulates medical devices in Turkey, and what are the core regulations?
Answer: The Turkish Medicines and Medical Devices Agency (TITCK, Turkiye Ilac ve Tibbi Cihaz Kurumu) under the Turkish Ministry of Health exercises unified oversight, covering market access, rule-making, market surveillance and approval of clinical investigations.
The core regulation is the Medical Device Regulation (Tibbi Cihaz Yonetmeligi), published in the Official Gazette on 2 June 2021 under No. 31499 (reissued number) and effective from 26 May 2021 except for a few provisions. Published in the same Gazette on the same day was the In Vitro Diagnostic Medical Device Regulation (In Vitro Tani Amacli Tibbi Cihazlar Yonetmeligi); IVDs follow this separate track.
That regulation repealed the former Medical Device Regulation and the Active Implantable Medical Device Regulation published in Official Gazette No. 27957 of 7 June 2011 (Article 110 of the Regulation), and was drafted with reference to EU Regulation 2017/745 (Article 109).
It has since been amended three times: 29 July 2022 (No. 31907), 2 April 2023 (No. 32151) and 17 August 2024 (No. 32635).
The umbrella law is Law No. 7223 on Product Safety and Technical Regulations, published on 12 March 2020 and effective 12 March 2021; penalties for violations also reference that law and the Turkish Penal Code.
In one sentence: for Turkish device rules, rely on the 2021 regulation plus its three amendments; any material predating 2021 should be discarded.
Q2 How does Turkish regulation relate to the EU MDR? Is CE marking automatically valid in Turkey?
Answer: Highly aligned, but this does not constitute mutual recognition.
The alignment shows at the technical level: classification rules, conformity assessment procedures, technical documentation, clinical evaluation, UDI, vigilance and market surveillance map almost one-to-one onto the EU MDR framework, and the group of products without a medical purpose in Annex XVI is also brought into scope.
But alignment is not mutual recognition. Turkey is not an EU member state; the legal effect of CE marking stops at the EU market. In Turkey, CE is the technical prerequisite for registration, while UTS registration is the legal prerequisite.
The two systems answer two different questions: CE answers whether the product meets safety and performance requirements; UTS answers whether this product may be placed on the Turkish market.
Note also an enforcement gap: the text of the regulation introduces EUDAMED registration obligations, but because EUDAMED is not yet fully operational, current enforcement and practice rely on the national UTS. When you see the claim that EUDAMED registration must be completed to enter Turkey, ask which point in time the claim is based on.
Q3 How are devices classified in Turkey, and what happens if the classification is wrong?
Answer: Consistent with Annex VIII of the EU MDR, devices fall into Class I, IIa, IIb and III under Rules 1-22; IVDs are graded separately as A-D.
Classification is determined by the manufacturer, which is accountable for its reasoning, but TITCK may challenge it during registration review, especially for three categories of borderline products: the device/cosmetics boundary (skin care and LED mask type products), software (Rule 11), and drug-device combination products.
The cost of a misclassification is not just changing a letter: it directly determines whether a notified body must be involved, the depth of the technical documentation, and the registration route and timeline. It is the most common and most underestimated cause of rework.
Note also that Annex XVI of the regulation brings products without a medical purpose under scope, including contact lenses, products that invasively alter anatomy through surgery, dermal fillers, liposuction/fat-dissolving equipment, laser and intense pulsed light equipment, and brain stimulation equipment; their obligations apply from six months after publication of the common specifications.
Q4 How does the IVD registration pathway differ from that of ordinary devices?
Answer: IVDs are governed by a separate regulation published on the same day, aligned with the EU IVDR (2017/746), graded A/B/C/D according to intended use and public health risk; Class D also involves common specifications.
Three key differences:
1. Do not apply the ordinary-device template. IVDs require performance evaluation, not clinical evaluation; analytical performance, clinical performance and scientific validity are the three pillars.
2. The classification logic differs. IVD classification looks not at invasiveness but at the public health and individual risk posed by an incorrect result.
3. Transition arrangements are dynamic. The EU IVDR transition periods have been extended repeatedly, and Turkey’s implementation pace adjusts accordingly; each case must be confirmed against the specific product and the latest announcements – copying the 2021 playbook is currently the most common systematic error in IVD submissions.
Q5 With only a CE certificate, can a product be sold in Turkey directly?
Answer: No. Look at it on three levels:
– Legal level: CE is a conformity mark under EU law; the condition for placing a device on the Turkish market is compliance with the Medical Device Regulation and completion of UTS registration – a different legal basis and a different enforcement authority.
– Technical level: the CE certificate (Class IIa and above) is a core document for registration, but TITCK will still verify four things: whether the certificate scope covers the declared models, whether the notified body is acceptable, whether the DoC version matches the certificate, and whether Turkish-language labelling and instructions for use are in place.
– Commercial level: even after registration, access to public hospitals and reimbursement requires passing the SGK/SUT gate separately (see Q20).
Remember the three layers in one line: CE decides whether you can apply, UTS decides whether you can sell, and SUT decides whether you get reimbursed.
Part 2: Entities and Responsibilities – Who Signs Before TITCK
Q6 Can a Chinese manufacturer complete Turkish registration on its own?
Answer: Not directly.
The regulation is explicit: a manufacturer without a place of business in an EU member state or in Turkey may place devices on the Turkish market only through a designated authorised representative (yetkili temsilci); the authorisation must be made in a written authorisation document (yetki belgesi) and submitted to TITCK. Chinese manufacturers are based neither in the EU nor in Turkey, so they must appoint an authorised representative in Turkey, who completes the company, document and product registrations in UTS.
There is a legal detail often overlooked: the regulation says ‘EU member state or Turkey’. This means that under the letter of the law, a manufacturer with a place of business in the EU need not additionally appoint a Turkish authorised representative; but the UTS system and the sales stage still require an economic operator in Turkey to take on the role, and in practice almost all foreign manufacturers – including EU manufacturers – appoint a local representative or importer.
Do not read this as ‘find a company to hang the registration on’: the authorised representative is a legally responsible party, not a mail-forwarding relay.
Q7 What exactly is the authorised representative responsible for, and what should you look at when choosing one?
Answer: Statutory duties include: verifying the manufacturer’s declaration of conformity and technical documentation, keeping copies of documents available for TITCK inspection, handling and maintaining registration and changes, serving as the statutory contact point for TITCK, assisting with vigilance reporting and recalls, and bearing the corresponding legal responsibility for device compliance within Turkey.
When selecting one, due diligence is recommended along four dimensions:
1. Authenticity of qualifications: whether it is a legal entity duly established in Turkey, whether it holds medical device trading qualifications, and whether it has completed company registration in UTS.
2. Conflicts of interest: if the party is also a distributor, registration ownership, document access rights and switch-out clauses must be written clearly at the start of cooperation, otherwise you can easily be locked into the channel later.
3. Contract terms: registration ownership, access to technical documentation, the division and deadlines for vigilance reporting, transitional obligations on change and termination, and stock and recall responsibilities – none of the five can be missing.
4. Capacity: whether it has dedicated staff with regulatory backgrounds. From 1 January 2025, device registration in UTS may only be handled by qualified personnel – a rule that directly eliminates a batch of agents with ‘nothing but a business licence’.
Q8 Must the manufacturer appoint a ‘person responsible for regulatory compliance’ in Turkey? What other entity obligations are commonly overlooked?
Answer: Yes. The regulation requires manufacturers to have at least one person responsible for regulatory compliance (PRRC) within the organisation and sets out one of two qualification routes:
– A formal qualification in law, medicine, pharmacy, engineering or another relevant discipline plus at least one year of practical experience in medical device regulatory affairs or quality management systems; or
– Four years of practical experience in medical device regulatory affairs or quality management systems.
Three entity obligations often overlooked:
1. Three systems must be ‘documented and auditable’: a risk management system (ISO 14971), a quality management system (ISO 13485) and a post-market surveillance system – all required, and mutually consistent.
2. Technical documentation is a living document: the declaration of conformity, clinical evaluation and risk analysis must be continuously updated as design and processes change; they are not one-off deliverables.
3. Retention period: technical documentation, the DoC and certificates must be kept for at least 10 years from the last device placed on the market (15 years for implantable devices).
Q9 What are the statutory obligations of importers and distributors?
Answer: Importers (ithalatci, Article 13 of the Regulation): verify that devices comply with the regulation and bear CE marking, have a DoC and technical documentation, indicate their own name/trade name/address on the device or its packaging, keep registration and complaint records, and cooperate with vigilance and recalls; they may not release products before confirming compliance.
Distributors (dagitici, Article 14 of the Regulation): verify CE marking and accompanying documents (including Turkish-language documents), not alter the condition of the device in ways that affect compliance, and cooperate with traceability and recalls.
Key insight: the Turkish ‘importer’ is a regulatory concept, not a customs clearance agent. The importer must be registered in UTS and ‘appear by name’ on the label – this directly determines who bears product liability before TITCK. Using a customs broker as the importer is the root cause of many projects’ problems at the market surveillance stage.
Part 3: UTS Registration – A Four-Step Process and Three Hard Constraints
Q10 What is UTS, and how many steps does registration take?
Answer: UTS (Urun Takip Sistemi, Product Tracking System) is TITCK’s mandatory electronic registration and traceability system, independent of the EU’s EUDAMED.
According to the registration process published by TITCK, devices must complete four steps in sequence to enter the Turkish market:
| Step | Content | Substance |
|---|---|---|
| 1. Company registration | Company Registration | The Turkish economic operator (manufacturer/authorised representative/importer) establishes the entity profile |
| 2. Document registration | Document Registration | Upload compliance documents such as the CE certificate and declaration of conformity |
| 3. Product registration | Product Registration | Create the product profile by GTIN/UDI-DI, linking manufacturer, classification, certificate and labelling |
| 4. Product actions | Product Actions | Circulation records for import, batches, stock and sales |
Three hard constraints:
1. Registration is not a ‘one-off filing’ but a continuously maintained ledger. Batches, stock and flows must all be kept moving.
2. Registration must match the physical product. If the economic operator, model or UDI on the label does not match the system records, questions arise directly at hospital acceptance and market surveillance. Note that product safety oversight at the import stage is enforced under Law No. 7223 and the annual Product Safety Surveillance Communique (e.g. No. 2025/16), whose inspection scope covers only the products listed in its annex – a logic separate from UTS registration; but UTS registration remains a precondition for placing a product on the market and for sale, so do not equate ‘customs cleared’ with ‘okay to sell’.
3. From 1 January 2025, only qualified personnel may handle UTS device registration (per TITCK’s Guide on the Implementation of the Regulation on the Sale, Advertisement and Promotion of Medical Devices). This is the procedural change in recent years with the greatest impact on Chinese manufacturers.
Q11 What documents are needed for UTS registration?
Answer: Following the TITCK process and practice, eight categories are usually involved:
1. Manufacturer entity documents (business licence, letter of authorisation), with a complete certification chain;
2. Entity documents and trading qualifications of the Turkish authorised representative/importer;
3. CE certificate (Class IIa and above) or declaration of conformity (Class I non-sterile, without measuring function);
4. ISO 13485 certificate;
5. Technical documentation (technical dossier, risk management, clinical evaluation);
6. Draft Turkish-language labels and instructions for use;
7. UDI/GTIN (GS1) information;
8. Classification rationale (including the rule basis).
Frequent rejection reasons are usually not ‘missing documents’ but three kinds of soft defects: substandard translation quality (especially intended use and instructions for use), a broken certification chain on the letter of authorisation (notarisation plus consular legalisation or an apostille), and certificate scope not matching the declared models.
Q12 How long does registration take, and how should the so-called ‘validity period’ be understood?
Answer: These two questions must be answered separately, because most circulating claims are inaccurate.
On timelines: Turkish official regulations and TITCK’s current UTS registration guide set no unified review deadline for all medical devices. The commonly cited 1 month to 3-6 months is an experience-based project estimate, not a regulatory commitment. The actual timeline depends on product classification, the readiness of company and authorised representative information, the completeness of conformity documents, notified body certificate verification, and whether deficiency corrections (eksiklik) arise. Generally, registration for Class I devices that are non-sterile, non-measuring and not reusable surgical instruments is relatively simple; Class I sterile, measuring or reusable surgical instruments and Class IIa and above usually require notified body involvement in conformity assessment, with relatively longer overall preparation and processing times.
On the ‘validity period’: a UTS product registration record is not a standalone registration certificate renewed every five years in the traditional sense. The product registration status must continuously rest on valid conformity documents, consistency of product information and the applicable regulatory requirements. For products requiring notified body involvement, the CE conformity certificate remains subject to the applicable validity rules; Article 56 of the MDR caps its validity at five years. The five-year validity of a CE certificate therefore cannot be directly applied as the validity of a UTS product registration.
Turkey manages product registration and the continuing compliance status, not a uniform five-year certificate renewal for all products. Successful UTS registration does not mean the product permanently holds market authorisation; the CE certificate, the declaration of conformity and change management still require continuous maintenance.
Q13 Are official fees high?
Answer: Official fees for routine medical device product registration in Turkey are relatively low and are not a major component of registration project costs. For example, per TITCK’s published 2026 fee schedule, the medical device product registration application fee is TRY 335, and the fee for registering EC certificates and declaration of conformity documents is TRY 335 per document. Specific amounts are subject to the fee schedule published at the time of application.
What really affects the project budget are the following four items:
1. Translation and preparation of Turkish-language labels, instructions for use and related submission documents;
2. Authorised representative service fees where applicable, and importer cooperation costs;
3. Technical documentation refinement, conformity assessment and possible deficiency-correction costs;
4. Post-market vigilance, PMS system setup and ongoing maintenance costs.
A rule of thumb for budgeting: official registration fees in Turkey are usually not the main cost; real investment goes into compliance document preparation, certificate scope checks, local representative responsibility arrangements, and ongoing post-market compliance management. The better the upfront documentation, the fewer later corrections and duplicate investments.
Q14 Do product changes or a change of authorised representative or importer require re-registration?
Answer: They must be declared, and the three types of change carry different risk levels.
1. Product changes (design, materials, intended use, adding/removing models): where the CE certificate is affected, update the certificate first, then update UTS – the order cannot be reversed.
2. Entity changes (replacing the authorised representative or importer): highest risk. Registration information, the economic operator on the label and the vigilance responsible party all change at once; you must ‘build first, then dismantle’ – the new representative completes registration before the old one is terminated, otherwise a dual vacuum in supply and compliance appears.
3. Registration information changes (address, name, classification): relatively simple, but likewise cannot be ‘patched afterwards’.
Note: changing representatives is called a ‘registration certificate transfer’ in some markets; in Turkey it is closer to ‘change of registered entity + re-linking of documents’. No certificate transfer is involved, but a complete chain of authorisation documents and the new representative’s capacity are still required. Without transitional clauses in the contract, this step becomes very passive.
Part 4: Documentation and Localization – Translation Is Not a ‘Language Issue’ but a ‘Compliance Issue’
Q15 Must labels and instructions for use be in Turkish?
Answer: Yes. Device labels and instructions for use must be in Turkish; devices for professional use may keep other languages as well, but Turkish is indispensable.
Content must cover: manufacturer and authorised representative/importer information, product name and intended use, batch/serial number, expiry date, UDI carrier and necessary warnings.
Three easy pitfalls:
1. ‘Translation’ is not ‘localization’. Symbols, units and warnings must follow Turkish usage and regulatory phrasing; literal translations will be questioned for readability during review.
2. Electronic instructions for use (e-IFU) are governed by a dedicated communique in Turkey; you cannot default to the EU’s e-IFU arrangements.
3. The economic operator information on the label must match the UTS registration, otherwise problems arise directly at customs clearance and hospital acceptance.
Q16 Must the entire technical file be translated into Turkish, and how long must it be kept?
Answer: Not all technical documentation needs full translation, but TITCK is entitled to request Turkish versions of key documents – intended use, labels, instructions for use, declaration of conformity. In practice, complete the Turkish localization of at least the ‘regulator-visible’ portion, i.e. what the reviewer will actually read.
Retention obligation: technical documentation, the DoC and certificates must be kept for at least 10 years from the last device placed on the market (15 years for implantables) and provided upon TITCK’s request.
The practical implication for Chinese manufacturers: the local representative must hold accessible copies of the documents. Files that exist ‘only on headquarters servers’ count as unavailable during market surveillance.
Q17 How do UDI, GS1 and UBB relate?
Answer: Three concepts, one chain.
– GS1 is the source of coding standards and issues GTINs;
– UDI is the regulatory concept: UDI-DI (corresponding to the GTIN) identifies the product model, and UDI-PI identifies batch/serial number/expiry;
– UBB (Ulusal Barkod Bilgi Bankasi, National Barcode Information Bank) is Turkey’s local barcode registration concept, interfacing with the UDI system, and should not be read as a separate coding system.
Three key points:
1. The GTIN must be registered under the manufacturer’s name. If the barcode owner does not match the declared manufacturer, registration will be blocked – a classic ‘basic but fatal’ error in cross-border projects.
2. UDI is not ‘print it and done’. It must form a closed loop with the UTS product profile, batch records and invoice data.
3. UDI requirements are strictest for implantables and Class III devices; carrier form and placement follow Annex VI of the regulation.
Part 5: Clinical and Post-Market – Deadlines Are Counted in Days
Q18 What approvals are needed to run a clinical investigation in Turkey?
Answer: TITCK authorisation and ethics committee review are required; the investigation must meet the requirements of the clinical investigations chapter of the Medical Device Regulation and follow national rules and international good clinical practice. The application is submitted to TITCK by the sponsor; foreign sponsors must act through a statutory representative in Turkey.
Three key points:
1. An existing CE certificate does not exempt the investigation from approval. CE addresses product compliance; investigation approval addresses the legality of studying the device on humans in Turkey – two separate tracks.
2. Import, labelling and informed consent for investigational devices all have separate requirements; the commercial import document package does not apply.
3. Agree on data ownership up front. Data from investigations in Turkey may support CE and registration clinical evaluation, but data ownership and usage rights must be written clearly in agreements, otherwise they cannot be cited later.
Q19 How quickly must adverse events and recalls be reported to TITCK?
Answer: Manufacturers must report all serious incidents and field safety corrective actions (FSCA) to TITCK. Deadlines are tiered by severity (Article 85 of the Regulation):
| Scenario | Reporting deadline |
|---|---|
| Serious threat to public health | No later than 2 days after awareness |
| Death or unexpected serious deterioration in a patient’s health | No later than 10 days after awareness |
| Other serious incidents | No later than 15 days after awareness |
| Field safety corrective action (FSCA) | Report ‘without delay’ before implementation (except in emergencies) |
Two technical points easily overlooked:
1. The clock starts on the ‘date of awareness’, not the ‘date the investigation is completed’. Many companies operate on ‘report after finding the cause’; in Turkey this constitutes a late report.
2. Handling restrictions during the investigation: the manufacturer must investigate without delay and, during the investigation, must not alter the device concerned or samples of the relevant batches without informing TITCK (Article 87 of the Regulation).
Supporting obligations: the manufacturer must run a post-market surveillance system and submit periodic safety update reports (PSUR) on the MDR model; the amendment of 17 August 2024 (Gazette No. 32635) also introduced an advance notice obligation for interruption of supply, mirroring EU Regulation 2024/1860.
Part 6: Commercial Reality – Registration Is Only the Entry Ticket
Q20 With UTS registration in hand, can a product enter public hospitals and reimbursement?
Answer: No. Market access in Turkey has three gates, independent of one another.
First gate: the right to sell. Under the Regulation on the Sale, Advertisement and Promotion of Medical Devices (Official Gazette No. 29001 of 15 May 2014), selling medical devices in Turkey requires a medical device sales centre authorisation certificate (tibbi cihaz satis merkezi yetki belgesi) and UTS registration; healthcare institutions and pharmacies may not purchase or use products not registered in UTS. This turns ‘registration’ from a manufacturer obligation into a customer acceptance condition.
Second gate: reimbursement. Managed by the Social Security Institution (SGK) under the Health Implementation Communique (SUT, Saglik Uygulama Tebligi), a track entirely separate from TITCK registration. Entering the SUT list requires a separate application, involving coding, pricing and clinical/economic justification. Products outside the SUT can still be sold through private channels, but large-scale public hospital procurement essentially depends on the SUT.
Third gate: public tenders. Tenders under the Public Procurement Law (Law No. 4734) usually require UTS registration and the corresponding SUT code for the products being bid.
Conclusion: registration is the ‘entry ticket’; the SUT is the ‘switch for scaled revenue’. Treating registration as the whole of market access is a common cause of blown budgets and timelines.
The three most expensive misconceptions
| Misconception | Fact |
|---|---|
| ‘With CE you can sell’ | CE is the technical prerequisite; UTS registration is the legal prerequisite; public channels add the SUT on top |
| ‘Turkey issues registration certificates renewed every five years’ | Turkey does not issue numbered registration certificates; the UTS registration record is the proof; its validity attaches to the CE certificate and registration information – there is no ‘five-year renewal’ |
| ‘Find any company to act as authorised representative’ | The authorised representative is a legally responsible party that must be qualified, registered in UTS and bear compliance responsibility; from 2025, registration may only be handled by qualified personnel |
Index of regulatory bases (for line-by-line verification)
| Topic | Basis |
|---|---|
| Regulator and core regulation | Medical Device Regulation, Official Gazette 2021-06-02 / No. 31499 (reissued number) |
| Separate IVD regulation | In Vitro Diagnostic Medical Device Regulation, published the same day in the same Gazette |
| Link with EU law and repeal of the old law | Articles 109 and 110 of the Medical Device Regulation |
| Three amendments | Official Gazette 2022-07-29 / 31907; 2023-04-02 / 32151; 2024-08-17 / 32635 |
| Umbrella law and penalties | Law No. 7223 on Product Safety and Technical Regulations (published 2020-03-12, effective 2021-03-12) |
| Classification rules and Annex XVI | Annex VIII (Rules 1-22) and Annex XVI of the Medical Device Regulation |
| Authorised representative | Provisions of the Medical Device Regulation on authorised representatives (mandatory for manufacturers without a place of business in the EU or Turkey) |
| Manufacturer, importer and distributor obligations | Articles 10, 13 and 14 of the Medical Device Regulation |
| Person responsible for regulatory compliance (PRRC) | Qualification and staffing requirements in the Medical Device Regulation |
| Vigilance deadlines and handling during investigations | Articles 85 and 87 of the Medical Device Regulation |
| Market surveillance and measures | Articles 90-94 of the Medical Device Regulation |
| UTS registration process (company/document/product/product actions) | TITCK’s official explanatory document ‘Medical Device Life Cycle’; TITCK ‘Guide to the UTS Registration Process for Medical Devices’ V4.0 (issued 2026-05-13) |
| Sales centre authorisation | Regulation on the Sale, Advertisement and Promotion of Medical Devices, Official Gazette 2014-05-15 / No. 29001 |
| Reimbursement | SGK Health Implementation Communique (SUT) |
| Public procurement | Public Procurement Law No. 4734 |
This article is compiled from the regulatory texts published in Turkey’s Official Gazette (Resmi Gazete) and publicly released TITCK documents, for industry exchange; it does not constitute legal advice or a regulatory commitment. Regulations may be amended; for classification decisions, document requirements and submission routes of specific projects, rely on the latest regulations, TITCK’s current announcements and official replies. Items without specific figures (such as review deadlines and official fee amounts) are either not stipulated in the regulations or subject to the announcements of the year in question; do not use them as a basis for quotations or schedules.